- Q1 2024 Taysha Gene Therapies Inc Earnings Call TranscriptMay 14, 2024$2.57 (+7.08%)Earnings
- Q4 2023 Taysha Gene Therapies Inc Earnings Call TranscriptMar 19, 2024$2.25 (+5.63%)Earnings
- Q3 2023 Taysha Gene Therapies Inc Earnings Call TranscriptNov 14, 2023$1.33Earnings
- Q2 2023 Taysha Gene Therapies Inc Earnings Call TranscriptAug 14, 2023$2.13 (+188.23%)Earnings
- Taysha Gene Therapies Inc R&D Day TranscriptJun 28, 2023
- Q1 2023 Taysha Gene Therapies Inc Earnings Call TranscriptMay 11, 2023$0.709 (-5.47%)Earnings
- Q4 2022 Taysha Gene Therapies Inc Earnings Call TranscriptMar 28, 2023$0.652 (-6.19%)Earnings
- Taysha Gene Therapies Inc Corporate Update Call TranscriptJan 31, 2023
- Q3 2022 Taysha Gene Therapies Inc Earnings Call TranscriptNov 08, 2022$2.2 (+10.00%)Earnings
- Taysha Gene Therapies Inc to Discuss Astellas Pharma's Strategic InvestmentCall TranscriptOct 25, 2022
- Q2 2022 Taysha Gene Therapies Inc Earnings Call TranscriptAug 11, 2022$3.95 (-19.06%)Earnings
- Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Taysha Gene Therapies Inc Earnings Call TranscriptMay 16, 2022$3.32 (-3.49%)Earnings
- Taysha Gene Therapies Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Taysha Gene Therapies Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) TranscriptApr 01, 2022
- Q4 2021 Taysha Gene Therapies Inc Earnings Call TranscriptMar 31, 2022$6.52 (+6.02%)Earnings
- Taysha Gene Therapies Inc To Discuss TSHA-120 GAN Program Update Call TranscriptJan 31, 2022
- Taysha Gene Therapies Inc To Discuss TSHA-101 In GM2 Gangliosidosis Program Update Call TranscriptJan 27, 2022
- Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Taysha Gene Therapies Inc Earnings Call TranscriptNov 10, 2021$15.74 (+5.14%)Earnings
- Taysha Gene Therapies Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- Taysha Gene Therapies Inc Angelman Syndrome Investor Day TranscriptOct 26, 2021
- Taysha Gene Therapies Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Taysha Gene Therapies Inc To Discuss CLN7 Program Acquisition Call TranscriptOct 05, 2021
- Taysha Gene Therapies Inc To Host Virtual Key Opinion Leader (KOL) Webinar On TSHA-102 For Treatment Of Rett Syndrome Call TranscriptSep 22, 2021
- Taysha Gene Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Taysha Gene Therapies Inc To Host CLN1 KOL Webinar TranscriptAug 30, 2021
- Q2 2021 Taysha Gene Therapies Inc Earnings Call TranscriptAug 16, 2021$15.82 (-8.98%)Earnings
- Taysha Gene Therapies Inc To Host Manufacturing Investor Day TranscriptJul 27, 2021
- Taysha Gene Therapies Inc R&D Day 2 TranscriptJun 29, 2021
- Taysha Gene Therapies Inc R&D Day 1 TranscriptJun 28, 2021
- Taysha Gene Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Taysha Gene Therapies Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Q1 2021 Taysha Gene Therapies Inc Earnings Call TranscriptMay 11, 2021$21 (+2.34%)Earnings
- Taysha Gene Therapies Inc GAN Program Acquisition Call TranscriptApr 12, 2021
- Full Year 2020 Taysha Gene Therapies Inc Earnings Call TranscriptMar 03, 2021$25.21Earnings
Taysha Gene Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody, and thanks for joining us for our last session here today. Very pleased to have Taysha with us.
Before we get started, I just need to read a quick disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
So pleased to have a broad range of the management team here. We have RA Session, the CEO; Suyash Prasad, who's the CMO. I think that's your title, Suyash, sorry; and Kamran Alam.
Questions & Answers
I thought maybe a good place to start because it's so recent is just the FDA obviously had their 2-day hearing on AAV. So I thought maybe you guys could just comment on what you thought are the key takeaways from that and any implications you see from that.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)